Mr. Andre Godin reports

INTELGENX RECEIVES APPROVAL TO CONDUCT 'MONTPARK' MONTELUKAST VERSAFILM(TM) PHASE 2 CLINICAL TRIAL IN PATIENTS WITH PARKINSON'S DISEASE

The Swedish Medical Products Agency, the Swedish Ethical Review Authority and the Regional Biobank Centre have approved the planned clinical study to investigate the use of IntelGenx Corp.'s Montelukast Versafilm for the treatment of Parkinson's disease.

PD is the second most common neurodegenerative disease after Alzheimer's disease, with an estimated nine million patients globally and one million patients in the United States. In the United States it is estimated that 90,000 new patients will be diagnosed with PD every year. No neuroprotective or disease-modifying treatments are currently available. The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa. Evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. Montelukast is a CysLT1 antagonist which decreases neuroinflammation by inhibiting CysLT1. Early results have indicated its potential usefulness for the treatment of various neurodegenerative disorders like PD and Alzheimer's disease.

The phase 2 Montpark study (CT No. 2023-504278-39-00) is a randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast Versafilm or placebo twice daily for 18 months, followed by a three-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. The study is expected to begin recruiting in first quarter 2024 with an expected study duration of approximately 24 to 30 months, depending on the recruitment rate.

The study will be conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx's previously announced research collaboration with Per Svenningsson, MD, PhD, who will serve as the study's principal investigator. Prof. Svenningsson will sponsor the study through a 20-million-Swedish-crown grant (approximately $2-million (U.S.)) awarded by the Swedish Research Council, Sweden's largest governmental research funding body.

"We are delighted that this trial has been approved by the MPA and look forward to beginning patient recruitment as soon as possible," said Dwight Gorham, IntelGenx's chief executive officer. "We are excited to be collaborating with Prof. Svenningsson, a PD pathogenesis expert who previously demonstrated the safety and tolerability of 40-milligram Montelukast in PD patients. Montpark will be evaluating daily Montelukast doses of 60 mg per day, making Montelukast Versafilm a more attractive dosing method due to its increased bioavailability (approximately 50-per-cent improvement over tablets) and minimizing the need on a daily basis for the requirement of numerous 10 mg Montelukast tablets."

Prof. Svenningsson stated, "Our study teams are quite eager and ready to commence the study with the novel IntelGenx Montelukast Versafilm due to the beneficial features of the film in terms of ease of use, better compliance and bioavailability."

About IntelGenx Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx's superior film technologies, including Versafilm, Disinteq, Vetafilm and transdermal Vevaderm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

We seek Safe Harbor.